David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.

(00:32)
Could you provide us with a little bit about yourself and your background?

(02:56)
Would you elaborate on the role of you and the Mayo Clinic team in advancing insights with the use of mass spectrometry and its initial launch?

(05:38)
Please share about Quantitative MASS-FIX and its specificity, and which patients should have this testing and when it should be performed.

(09:42)
Is this a more simplified ordering menu?

(15:01)
Would you elaborate on how this assay supports the IMWG guidelines?

(16:01)
Are there any closing remarks you would like to add?